All News

20 May 2008

Denosumab Osteoporosis Study Meets Primary and All Secondary Bone Mineral Density Endpoints in Alendronate (FOSAMAX(R)) Transition StudyAntibodies

19 May 2008

Schering-Plough Extends Antibody Alliance with MorphoSysAntibodies

19 May 2008

Patient recruitment started in Phase III registration trial with CA9-SCANAntibodies

16 May 2008

ERBITUX(R) (cetuximab) Data Demonstrate Improvements in Response Rate and Progression-Free Survival in Wild Type K-Ras Metastatic Colorectal Cancer Patients in First-Line SettingAntibodies

15 May 2008

Lpath’s iSONEP(TM) IND Application Gets Green Light From FDAAntibodies

13 May 2008

Active Biotech advances ANYARA into Phase III clinical trialAntibodies

13 May 2008

Start of Phase II Clinical Study for Rabies Monoclonal Antibody Combination in the PhilippinesAntibodies

13 May 2008

Affimed validates antibody target for cancer metastasisAntibodies

13 May 2008

Phase II Study of IMC-A12 for Advanced Liver Cancer Opens for Patient EnrollmentAntibodies

12 May 2008

Medarex Announces Initiation of Phase 2 Clinical Trials for the Treatment of Ulcerative Colitis and Rheumatoid ArthritisAntibodies

9 May 2008

Actemra inhibits joint damage and improves physical function of patients with Rheumatoid ArthritisAntibodies

8 May 2008

Trubion Announces Initiation of Phase 2b Study of TRU-015 for the Treatment of Rheumatoid ArthritisAntibodies

8 May 2008

Bayer and Regeneron start additional Phase 3 Study for VEGF Trap-Eye in Wet Age-related Macular DegenerationAntibodies

30 April 2008

Merck Serono and ZymoGenetics Initiate Atacicept Phase 2 Clinical Trial in Relapsing Multiple SclerosisAntibodies

29 April 2008

Genentech and Biogen Idec Announce Top-Line Results From Phase II/III Clinical Study of Rituxan in Systemic Lupus ErythematosusAntibodies

29 April 2008

Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Bavituximab Phase II Breast Cancer TrialAntibodies

28 April 2008

Medarex and Bristol-Myers Squibb Joint Statement on Submission Status of IpilimumabAntibodies

28 April 2008

KaloBios Completes Patient Dosing in its U.S. Phase 1 Trial of Its Third Drug Candidate, KB003Antibodies

28 April 2008

Regeneron and Bayer HealthCare Announce Encouraging 32-Week Follow-Up Results from a Phase 2 Study of VEGF Trap-Eye in Age-Related Macular DegenerationAntibodies

28 April 2008

MorphoSys Announces Completion of First Dosing in Phase 1 Trial for MOR103 ProgramAntibodies

24 April 2008

Arana and Kyowa Hakko to co-develop anti-cancer drugAntibodies

24 April 2008

MorphoSys and the Leibniz-Institut für Molekulare Pharmakologie Sign Broad Research PartnershipAntibodies

24 April 2008

ESBATech’s Lead Antibody Fragment Enters Clinical Development for Ophthalmic IndicationsAntibodies

23 April 2008

Micromet Enrolls First Patient in Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid TumorsAntibodies

23 April 2008

ImClone Announces Agreement with FDA on Special Protocol Assessment for Phase III Study of IMC-1121B in Breast CancerAntibodies

23 April 2008

Single, Intramuscular (IM) Dose, Protects up to 75 Percent in Primate StudyAntibodies

22 April 2008

CimziaA(R) Approved in the US for the Treatment of Moderate to Severe Crohn’s DiseaseAntibodies

22 April 2008

Human Genome Sciences completes enrollment in first of two phase 3 LYMPHOSTAT-B(R) trialsAntibodies

21 April 2008

Trubion Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Rheumatoid ArthritisAntibodies

21 April 2008

Cancer Treatment Pioneer, Lpath, Initiates Dosing in Phase 1 Cancer TrialAntibodies

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

Antibody Target, Technology & Pipeline Database: 1-Year Subscription

Targeted Protein Degradation by Proteasomal, Lysosomal & Autophagy Pathways 2022: an industry landscape analysis of stakeholders, technologies, pipeline, partnering and financing

B7-H4 Targeted Antibody Therapy Pipeline Review

Claudin 6, Cadherin 17, ROR1 and GPRC5D-Targeted Therapies: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis

CD40 Agonists & CD40/L Antagonists Pipeline Review

Omalizumab (Xolair) Biosimilars & Biosuperiors Pipeline Review

CCR8-Targeted Antibody Immunotherapy Pipeline Review

Intracellular Targets made druggable by TCR-like Antibodies, TCR Fusion Proteins & Cell-Penetrating Biologics 2018: an industry analysis of technologies, stakeholders, deals & trends

2020 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics

Folate Receptor alpha (FRα) Targeted Therapy Pipeline Review